The neofleX is compatible with existing Bruker software and hardware. Credit: testing / Shutterstock.

Bruker has launched its neofleX Imaging Profiler MALDI-TOF/TOF for mass spectrometry imaging (MSI) applications.

Suitable for mass spectrometry-based tissue imaging, Bruker states that the device addresses the unmet needs of moving from discovery imaging to translational and clinical tissue research.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

NeofleX is also compatible with the MALDI-ISH method announced at ASMS 2024 by AmberGen.

MALDI-ISH multiplexes imaging of up to 12 oligomers of interest (RNA/DNA) for multi-omic spatial tissue research in neuroscience, infectious disease, and oncology.

In addition, the company says the neofleX excels at providing more insight per pixel through multi-omic spatial biology data from tissue sections that can positively correlate targeted proteins with glycans, metabolites, lipids, endogenous peptides, xenobiotics, and now RNA/DNA.

The neofleX is compatible with existing Bruker software and hardware, including its MALDI Imaging software and consumables ecosystems such as IntelliSlides and SCiLSautopilot – tools intended to simplify sample tracking, preparation, and analysis and to automate mass-spec imaging runs.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to Dr Michael Easterling, vice president of MSI for Bruker’s life sciences mass spectrometry division, the device’s multimodal software and workflows on the benchtop will support a range of biopharma and clinical research tasks.

Easterling said: “NeofleX brings novel capabilities to spatial biology, including spatial proteomics combined with unique multiomics correlations for developing actionable biological insights.”

The device’s launch follows Bruker’s recent acquisition of ELITechGroup for $942m.

Last year, Bruker entered a partnership with Advanced Diagnostics to validate the use of the company’s respective Arc and MALDI Biotyper systems.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact